Tempest Therapeutics, Inc.
TPST · XNASCIK 1544227fmd_05185THPF8BZE026HQSDHH63KX制造业 · 医药制剂模板: 标准
覆盖范围: 2011年1月01日 至 2026年6月30日，共 61 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | 1 | 0 | – | – | – | – | – | – | – | – |
| 营业成本 | 5 | 1 | – | – | – | – | – | – | – | – |
| 毛利润 | (5) | (0) | – | – | – | – | – | – | – | – |
| 研发费用 | 22 | 15 | 14 | 28 | 14 | 17 | 23 | 17 | 28 | 13 |
| 销售、一般及管理费用 | 49 | 28 | – | – | – | – | – | – | – | – |
| 营业费用合计 | 82 | 51 | – | – | – | – | – | – | – | – |
| 营业利润 | (81) | (84) | (27) | (45) | (19) | (27) | (35) | (29) | (42) | (27) |
| 利息费用 | – | 0 | 0 | – | 0 | 1 | 2 | 1 | 1 | 0 |
| 利息及投资收益 | – | – | – | – | – | – | – | – | – | – |
| 其他营业外收入（支出） | (0) | (0) | – | – | 0 | (1) | (1) | (0) | 0 | 0 |
| 税前利润 | (82) | (51) | – | – | – | – | – | – | – | – |
| 所得税费用 | 0 | 0 | – | – | 0 | 0 | 0 | 0 | 0 | 0 |
| 持续经营净利润 | (82) | (51) | – | – | – | – | – | – | – | – |
| 净利润 | (82) | (85) | (27) | (45) | (19) | (28) | (36) | (29) | (42) | (26) |
| 归属于普通股股东的净利润 | (82) | (51) | – | – | – | – | – | – | – | – |